Iontophoresis — CPB 0229 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0229 governing iontophoresis coverage, effective September 26, 2025. Billing teams need to verify diagnosis codes and step-therapy documentation before submitting claims under CPT 97033 or CPT 89230.

Aetna iontophoresis coverage policy CPB 0229 now defines four specific covered indications, with tight medical necessity criteria for the most commonly billed use — primary focal hyperhidrosis. The two covered CPT codes are 97033 (iontophoresis treatment, each 15 minutes) and 89230 (sweat collection by iontophoresis for cystic fibrosis diagnosis). If your billing team submits 97033 for hyperhidrosis without documented step-therapy failure, expect a claim denial.

Quick-Reference Table

Aetna Iontophoresis Coverage Criteria and Medical Necessity Requirements 2025

Aetna's coverage policy recognizes four covered indications for iontophoresis. Two of them — local anesthetic delivery before emergent skin puncture or dermatological procedures, and iontophoretic fentanyl for post-operative pain — have relatively clean documentation paths. The other two require more careful chart review before you bill.

The hyperhidrosis indication is where most denials will happen. Aetna requires all three of the following before medical necessity is established: the member must be unresponsive to or unable to tolerate oral pharmacotherapy (anti-cholinergics, beta-blockers, or benzodiazepines), excessive sweating must cause significant disruption to professional or social life, and topical aluminum chloride or extra-strength anti-perspirants must be ineffective or cause severe rash. All three must be documented. Missing one means the claim fails medical necessity review.

The cystic fibrosis indication is more straightforward. CPT 89230 (sweat collection by iontophoresis) maps to ICD-10 codes E84.0 through E84.9. This is a diagnostic use, not a therapeutic one, and the documentation bar is lower — but the diagnosis code must be present on the claim.

Iontophoretic fentanyl for post-operative pain (G89.12 for acute post-thoracotomy pain, G89.18 for other acute post-operative pain) is explicitly covered under this coverage policy. This is a narrow indication — it covers acute post-operative pain management only, not chronic pain or other fentanyl delivery contexts.

Aetna's billing guidelines for CPB 0229 in Aetna's system do not list a blanket prior authorization requirement for iontophoresis. That said, prior auth requirements can vary by plan, so check the member's specific plan before assuming a clean submission. If you're unsure, call the number on the back of the member's card and document the response.

Aetna Iontophoresis Exclusions and Non-Covered Indications

The policy is clear about what doesn't get reimbursement: acetic acid iontophoresis and ascorbic acid iontophoresis are not covered. Aetna has listed three HCPCS codes in the non-covered group, which signals that any billing attempt for these uses will be denied.

J2787 (riboflavin 5'-phosphate ophthalmic solution, up to 3 mL) appears in the non-covered group. This code is associated with corneal cross-linking procedures. Its inclusion here tells you that Aetna is not covering any iontophoretic delivery of riboflavin under this policy.

J3285 and J7686 — both associated with treprostinil — are also listed as non-covered under iontophoresis administration. Treprostinil is a prostacyclin analog used in pulmonary arterial hypertension. Aetna is drawing a hard line: iontophoretic delivery of this drug does not qualify for coverage under CPB 0229, regardless of diagnosis.

The real issue here is that the ICD-10 code list for this policy is long — 152 codes, spanning everything from herpesviral ocular disease to Parkinson's to carpal tunnel syndrome. Most of those diagnoses don't map to any of the four covered indications. A code appearing on the ICD-10 list does not automatically mean the service is covered. The indication still has to match. Don't let a long code list create a false sense of coverage breadth.

Coverage Indications at a Glance

Aetna Iontophoresis Billing Guidelines and Action Items 2025

The effective date is September 26, 2025. If your practice regularly bills CPT 97033 or 89230 to Aetna, these steps need to happen before that date.

If your practice has high Aetna volume and you bill iontophoresis across multiple specialties, loop in your compliance officer before September 26. The hyperhidrosis criteria in particular create real exposure if documentation hasn't been consistently captured.

CPT, HCPCS, and ICD-10 Codes for Iontophoresis Under CPB 0229

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered HCPCS Codes

Key ICD-10-CM Diagnosis Codes

Note: The full ICD-10 list in CPB 0229 contains 152 codes. A code appearing on this list does not automatically mean iontophoresis is covered for that diagnosis. Coverage depends on the indication matching one of the four covered uses above.